Discover the most recent news about our Company.
Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has become one of the
Visualizing cardiovascular risk in a single image As science advances, the amount of data generated to assess cardiovascular risk (CVR)
LDL-C as a Traditional Therapeutic Target Historically, LDL-C has been maintained as the primary therapeutic target in the prevention of
Low-Grade Inflammation: The Invisible Thread Connecting Obesity and Cardiometabolic Risk Obesity is not merely an excess of weight; it is
A recent study published in Lipids in Health and Disease (Santisteban et al., 2025) offers a new perspective on how
Gut microbiota and metabolism associated with CAR-T therapy response in multiple myeloma A recent work published by Mireia
Triglycerides: More Than a Marker — A Driver of Cardiovascular Risk Introduction: The Residual Risk Beyond LDL Cholesterol
ASCAHIFA and Biosfer Teslab join forces to advance the diagnosis of familial hypercholesterolemia with Liposcale® On September 24, we celebrate
The Challenge of Residual Risk in Cardiovascular Health Cardiovascular diseases remain the leading cause of death worldwide.Despite preventive
In biomedical research, animal models represent a fundamental tool for understanding the pathophysiological mechanisms of human diseases and
Each year, cardiovascular diseases (CVD) are responsible for more than 4 million deaths in Europe, making them the leading
Each year, cardiovascular diseases (CVD) are responsible for more than 4 million deaths in Europe, making them the leading